We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Swissmedic Limits Approval Pathway for Heparin-Based Biosimilars
Swissmedic Limits Approval Pathway for Heparin-Based Biosimilars
Switzerland’s medicines authority said last month that it will not accept marketing authorization applications for biosimilars of low-molecular-weight heparin products already approved there.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor